EXELIXIS, INC.
For the period ended Jan 2, 2026. Filed Feb 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Feb 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Jack L. Wyszomierski, amember of our Board of Directors, entered into a pre-arranged stock trading plan on November 19, 2025. Mr. Wyszomierski’s trading plan provides for the sale of up to 114,746 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between February 18, 2026 and November 19, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
S. Gail Eckhardt, amember of our Board of Directors, entered into a pre-arranged stock trading plan on November 11, 2025. Dr. Eckhardt’s trading plan provides for the sale of up to 13,668 shares of our common stock between February 13, 2026 and June 30, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
On November 19, 2025, Brenda J. Hefti, our Senior Vice President and General Counsel, an officer for purposes of Section 16 of the Exchange Act, modified an existing 10b5-1 trading plan that was originally entered on February 26, 2025. Dr. Hefti’s modified trading plan provides for the sale of up to 30,202 shares of our common stock between February 18, 2026 and May 29, 2026. This modified trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
During the three months ended December 31, 2025, no other directors or Section 16 officers of the Company adopted, modified or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.